Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 8/2017

13.05.2017 | Focussed Research Review

Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments

verfasst von: Sabina Sangaletti, Claudia Chiodoni, Claudio Tripodo, Mario P. Colombo

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

The complex interaction between cells undergoing transformation and the various stromal and immunological cell components of the tumor microenvironment (TME) crucially influences cancer progression and diversification, as well as endowing clinical and prognostic significance. The immunosuppression characterizing the TME depends on the recruitment and activation of different cell types including regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages. Less considered is the non-cellular component of the TME. Here, we focus on the extracellular matrix (ECM) regulatory activities that, within the TME, actively contribute to many aspects of tumor progression, acting on both tumor and immune cells. Particularly, ECM-mediated regulation of tumor-associated immunosuppression occurs through the modulation of myeloid cell expansion, localization, and functional activities. Such regulation is not limited to the TME but occurs also within the bone marrow, wherein matricellular proteins contribute to the maintenance of specialized hematopoietic stem cell niches thereby regulating their homeostasis as well as the generation and expansion of myeloid cells under both physiological and pathological conditions. Highlighting the commonalities among ECM-myeloid cell interactions in bone marrow and TME, in this review we present a picture in which myeloid cells might sense and respond to ECM modifications, providing different ECM-myeloid cell interfaces that may be useful to define prognostic groups and to tailor therapeutic interventions.
Literatur
2.
Zurück zum Zitat Acerbi I, Cassereau L, Dean I et al (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7:1120–1134. doi:10.1039/c5ib00040h CrossRef Acerbi I, Cassereau L, Dean I et al (2015) Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration. Integr Biol (Camb) 7:1120–1134. doi:10.​1039/​c5ib00040h CrossRef
8.
Zurück zum Zitat Bergamaschi A, Tagliabue E, Sørlie T et al (2008) Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 214:357–367. doi:10.1002/path.2278 CrossRefPubMed Bergamaschi A, Tagliabue E, Sørlie T et al (2008) Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol 214:357–367. doi:10.​1002/​path.​2278 CrossRefPubMed
13.
18.
27.
Zurück zum Zitat Kaplan G (1983) In vitro differentiation of human monocytes. Monocytes cultured on glass are cytotoxic to tumor cells but monocytes cultured on collagen are not. J Exp Med 157:2061–2072CrossRefPubMed Kaplan G (1983) In vitro differentiation of human monocytes. Monocytes cultured on glass are cytotoxic to tumor cells but monocytes cultured on collagen are not. J Exp Med 157:2061–2072CrossRefPubMed
30.
Zurück zum Zitat Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531. doi:10.1038/nri3024 CrossRefPubMed Mantovani A, Cassatella MA, Costantini C, Jaillon S (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 11:519–531. doi:10.​1038/​nri3024 CrossRefPubMed
37.
38.
Zurück zum Zitat Tripodo C, Sangaletti S, Guarnotta C et al (2012) Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 120:3541–3554. doi:10.1182/blood-2011-12-398537 CrossRefPubMed Tripodo C, Sangaletti S, Guarnotta C et al (2012) Stromal SPARC contributes to the detrimental fibrotic changes associated with myeloproliferation whereas its deficiency favors myeloid cell expansion. Blood 120:3541–3554. doi:10.​1182/​blood-2011-12-398537 CrossRefPubMed
40.
42.
Zurück zum Zitat Pellagatti A, Cazzola M, Giagounidis A et al (2007) Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes. Leuk Res 31:S35-S. doi:10.1016/S0145-2126(07)70061-9 CrossRef Pellagatti A, Cazzola M, Giagounidis A et al (2007) Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes. Leuk Res 31:S35-S. doi:10.​1016/​S0145-2126(07)70061-9 CrossRef
47.
48.
Zurück zum Zitat Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Cancer Res 72(Suppl):SY28-02. doi:10.1158/1538-7445.Am2012-Sy28-02 Malanchi I, Santamaria-Martinez A, Susanto E, Peng H, Lehr HA, Delaloye JF, Huelsken J (2012) Interactions between cancer stem cells and their niche govern metastatic colonization. Cancer Res 72(Suppl):SY28-02. doi:10.1158/1538-7445.Am2012-Sy28-02
50.
Zurück zum Zitat Condamine T, Dominguez GA, Youn JI, et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunol 1:aaf8943. doi:10.1126/sciimmunol.aaf8943 Condamine T, Dominguez GA, Youn JI, et al (2016) Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Science Immunol 1:aaf8943. doi:10.​1126/​sciimmunol.​aaf8943
Metadaten
Titel
Common extracellular matrix regulation of myeloid cell activity in the bone marrow and tumor microenvironments
verfasst von
Sabina Sangaletti
Claudia Chiodoni
Claudio Tripodo
Mario P. Colombo
Publikationsdatum
13.05.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 8/2017
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-2014-y

Weitere Artikel der Ausgabe 8/2017

Cancer Immunology, Immunotherapy 8/2017 Zur Ausgabe

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.